NASDAQ:RXRX Recursion Pharmaceuticals Q3 2024 Earnings Results & Report $3.84 -0.17 (-4.24%) Closing price 04:00 PM EasternExtended Trading$3.85 +0.01 (+0.16%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Recursion Pharmaceuticals missed analyst earnings expectations but beat on revenue in its Q3 2024 results, released November 6, 2024. The company reported EPS of -$0.34 versus the -$0.33 consensus estimate, while revenue of $26.08 million topped the $12.62 million estimate by $13.46 million. Revenue increased 147.6% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 6, 2024TimeAfter Market ClosesConference Call2:30 AM ET Recursion Pharmaceuticals EPS ResultsActual EPS-$0.34Consensus EPS -$0.33Beat/MissMissed by -$0.01One Year Ago EPS-$0.43EPS Beat Rate3 of last 8 quartersRecursion Pharmaceuticals Revenue ResultsActual Revenue$26.08 millionExpected Revenue$12.62 millionBeat/MissBeat by +$13.46 millionYoY Revenue Growth+147.60%Upcoming EarningsRecursion Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Recursion Pharmaceuticals Q3 2024 Earnings FAQ Did Recursion Pharmaceuticals beat earnings estimates for Q3 2024? Recursion Pharmaceuticals (NASDAQ:RXRX) reported earnings of -$0.34 per share for Q3 2024, missing the consensus estimate of -$0.33. The report was announced on Wednesday, November 6, 2024. What was Recursion Pharmaceuticals' revenue for Q3 2024? Recursion Pharmaceuticals reported revenue of $26.08 million for Q3 2024, against a consensus estimate of $12.62 million. When is Recursion Pharmaceuticals' next earnings date? Recursion Pharmaceuticals' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Recursion Pharmaceuticals on the company's earnings history page. Recursion Pharmaceuticals Earnings HeadlinesWhat Could Go Wrong With Recursion Pharmaceuticals Stock?October 10 at 3:46 AM | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Blake Borgeson Sells 50,000 SharesOctober 9, 2026 | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)October 7, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10% - Here's WhyOctober 5, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) and Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head ComparisonOctober 5, 2026 | americanbankingnews.comSee More Recursion Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Recursion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your email. Email Address About Recursion PharmaceuticalsRecursion Pharmaceuticals (NASDAQ:RXRX) is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms. Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience. Its pipeline has included internally discovered and developed drug candidates, as well as programs advanced through collaborations and strategic partnerships. The company’s approach combines laboratory experimentation with computational tools to support target discovery, compound design, preclinical testing and clinical development. Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion operates as an international biotechnology organization through its research activities, partnerships and collaborations. In 2024, Recursion completed a combination with Exscientia plc, a United Kingdom-based company specializing in artificial intelligence-driven drug design, expanding Recursion’s capabilities in computational chemistry and medicine discovery. Recursion was co-founded by Chris Gibson, who serves as chief executive officer.View Recursion Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
